JPRN-UMIN000030780已完成3 期
Phase 3 Trial of Carboplatin in Triple Negative Breast Cancer Patient with Residual Invasive Carcinoma After Neoadjuvant Chemotherapy(Transitioned to jRCT) - P3 Trial of Cb on non pCR TNBC
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1) previously treated with Carboplatin (2) other cancer (3) bilateral breast cancer (4) during pregnancy or breast feeding (5) attended clinical trial within 6 month (6) metastatic breast cancer (7) heavy disorder of heat, kidney or liver (8) doctor's dicision of inadequacy
研究者
相似试验
招募中
3 期
Phase 3 Trial of Carboplatin in Triple Negative Breast Cancer Patient with Residual Invasive Carcinoma After Neoadjuvant ChemotherapyJPRN-jRCTs051180210Kunihisa Tomonari162
进行中（未招募）
1 期
Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerewly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerEUCTR2014-005070-11-PLAbbVie Deutschland GmbH & Co. KG1,100
进行中（未招募）
1 期
Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerEUCTR2014-005070-11-DKAbbVie Deutschland GmbH & Co. KG1,100
进行中（未招募）
1 期
Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerewly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancerEUCTR2014-005070-11-ESAbbVie Deutschland GmbH & Co. KG1,100
Unknown
3 期
Triple Negative Breast Cancer TrialBreast CancerNCT00532727Institute of Cancer Research, United Kingdom400